Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
NEW YORK, Oct.7, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
The Asset Purchase Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the asset purchase agreements entered into by the worlds leading biopharma companies. The report provides a detailed understand and analysis of how and why companies enter asset purchase deals.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all asset purchase deals announced since 2009 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual asset purchase contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
The initial chapters of this report provide an orientation of asset purchase dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in asset purchase as well as a discussion on the merits of the type of deal.
Chapter 3 provides an overview of the structure of asset purchase deals. The chapter includes numerous case studies to enable understanding of both pure asset purchase deals and multicomponent deals where asset purchase forms a part.
Chapter 4 provides a review of the leading asset purchase deals since 2009. Deals are listed by headline value, signed by bigpharma and biobiotech, most of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of asset purchase deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive listing of the top 50 big biotech companies with a brief summary followed by a comprehensive listing of asset purchase deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 7 provides a comprehensive and detailed review of asset purchase deals signed and announced since 2009 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the asset purchase deal.
In addition the report includes a comprehensive listing of all asset purchase deals announced since 2009.
Each listing is organized as an appendix by company A-Z, stage of development at signing, and therapeutic area. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
The report also includes numerous table and figures that illustrate the trends and activities in asset purchase dealmaking since 2009.
In conclusion, this report provides everything a prospective dealmaker needs to know about asset purchase alliances.
Asset Purchase Partnering Terms and Agreements in Pharma, Biotech and Diagnostics provides the reader with the following key benefits:
In-depth understanding of asset purchase deal trends since 2009
Analysis of the structure of asset purchase agreements with numerous real life case studies
Comprehensive access to over 1,000 actual asset purchase deals entered into by the world's biopharma companies
Detailed access to actual asset purchase deals entered into by the leading fifty big pharma and big biotech companies
Insight into the terms included in a asset purchase agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Asset Purchase Partnering Terms and Agreements in Pharma, Biotech and Diagnostics is intended to provide the reader with an in-depth understanding of the asset purchase trends and structure of deals entered into by leading biopharma companies worldwide.Asset Purchase Partnering Terms and Agreements in Pharma, Biotech and Diagnostics includes:
Trends in asset purchase dealmaking in the biopharma industry since 2009
Analysis of asset purchase deal structure
Case studies of real-life asset purchase deals
Access to over 1,000 asset purchase deal records
The leading asset purchase deals by value since 2009
Most active asset purchase dealmakers since 2009
The leading asset purchase partnering resources
In Asset Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, the available deals are listed by:
Stage of development at signing
Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
Chapter 1 – Introduction
Chapter 2 – Trends in asset purchase dealmaking
2.1. Introduction2.2. Types of assets purchased2.3. Trends in asset purchase deals since 20092.3. Reasons for entering into asset purchase partnering deals2.3.1. Business assets2.3.2. Product assets2.3.3. Royalty assets2.3.4.Technology assets2.4 The emergence of royalty asset purchase deals2.4.1. Primary players in royalty asset purchase deals2.4.2. Recent royalty asset purchase deals2.4.3. The future of royalty asset purchase deals2.5. The role of IP auction houses in asset purchase deals2.5.1. Leading IP auction companies2.6. The future of asset purchase agreements
Chapter 3 – Overview of asset purchase deal structure
3.2. Asset purchase agreement structure
3.3. Example asset purchase agreements
3.3.1. Case study 1: Product asset: QLT – Valeant Pharmaceuticals
3.3.2. Case study 2: Business asset: Enzon Pharmaceuticals – Sigma-Tau
3.4. Anatomy of a royalty asset purchase agreement
3.5. Example royalty asset purchase agreements
3.5.1. Case study 3: Royalty asset: DRI Capital – NPS Pharmaceuticals
Chapter 4 – Leading asset purchase deals
4.1. Introduction4.2. Top asset purchase deals by value4.3. Most active asset purchase dealmakers4.4. Bigpharma asset purchase deal activity4.5. Bigbiotech asset purchase deal activity
Chapter 5 – Bigpharma asset purchase deals
5.2. How to use asset purchase deals
5.3. Bigpharma company asset purchase deal profiles
Johnson & Johnson
Kyowa Hakko Kirin
Merck & Co
Chapter 6 – Bigbiotech company asset purchase deals
6.1. Introduction6.2. How to use bigbiotech partnering deals6.3. Bigbiotech asset purchase partnering company profilesAcorda TherapeuticsActelionAlexion PharmaceuticalsBioconBioMarin PharmaceuticalsCelgeneDendreonElanEmergent BioSolutionsGalapagosGilead SciencesGrifolsIpsenNovo NordiskPDL BioPharmaRegeneron PharmaceuticalsSciClone PharmaceuticalsShireSpectrum PharmaceuticalsViroPharma
Chapter 7 – Asset purchase contracts directory
7.2. Company A-Z
7.3. By stage of development
7.4. By therapeutic target
7.5. By technology type
About Wildwood VenturesCurrent PartneringCurrent AgreementsRecent report titles from CurrentPartneringOrder Form – ReportsOrder Form – Reports
Appendix 1- Company A-ZAppendix 2- By therapy areaAppendix 3-By stage of development at signingAppendix 4- By technology typeAppendix 5- Asset purchase dealmaking referencesAppendix 6- ResourcesAppendic 7- Deal type definitionsAppendix 8-Example asset purchase contract document
TABLE OF FIGURES
Figure 1: Definition of assets purchasedFigure 2: Trends in asset purchase deal announcements, 2009-2013Figure 3: Leading royalty asset investorsFigure 4: Recent royalty asset purchase agreementsFigure 5: Leading IP auction companiesFigure 6: Components of the asset purchase deal structureFigure 7: Components of the royalty asset purchase deal structureFigure 8: Top asset purchase deals by value since 2009Figure 9: Most active asset purchase dealmakers 2009-2013Figure 10: Bigpharma – top 50 – asset purchase deals 2009 to 2013Figure 11: Bigpharma asset purchase deal frequency - 2009 to 2013Figure 12: Bigbiotech – top 50 – asset purchase deals 2009 to 2013Figure 13: Bigbiotech asset purchase deal frequency - 2009 to 2013To order this report: Asset Purchase Terms and Agreements in Pharma, Biotech and Diagnostics http://www.reportlinker.com/p01593887/Asset-Purchase-Terms-and-Agreements-in-Pharma-Biotech-and-Diagnostics.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Diagnostics
Contact Clare: email@example.com
US:(339) 368 6001
Intl:+1 339 368 6001
©2012 PR Newswire. All Rights Reserved.